Literature DB >> 2242606

Increased production of the third component of complement (C3) by monocytes from patients with systemic lupus erythematosus.

H Tsukamoto1, A Ueda, K Nagasawa, Y Tada, Y Niho.   

Abstract

We measured in vitro C3 production by peripheral blood monocytes from patients with systemic lupus erythematosus (SLE), and found it to be significantly greater than that from normal controls. We also found that monocytes from SLE patients with active disease produced a markedly larger amount of C3 than those from SLE patients with inactive disease. Production of C3 by monocytes correlated with serum levels of anti-dsDNA antibodies and inversely correlated with serum C3 levels in SLE patients. Serial measurement of C3 in the culture supernatant from each SLE patient showed that C3 production by monocytes fell in parallel with a decrease of disease activity. The effect of corticosteroids was ruled out as there was no relation between the level of C3 production by monocytes and the dose of prednisolone. This seems to be the first study in which the C3 production was assayed at a cellular level in SLE patients, and this study suggests that the local C3 production is increased in SLE patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2242606      PMCID: PMC1535108          DOI: 10.1111/j.1365-2249.1990.tb05436.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  26 in total

1.  The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations.

Authors:  A S Fauci; B Haynes; P Katz
Journal:  Ann Intern Med       Date:  1978-11       Impact factor: 25.391

2.  C3 component of complement secreted by established cell lines.

Authors:  D R Senger; R O Hynes
Journal:  Cell       Date:  1978-10       Impact factor: 41.582

3.  The lupus activity criteria count (LACC).

Authors:  M B Urowitz; D D Gladman; E C Tozman; C H Goldsmith
Journal:  J Rheumatol       Date:  1984-12       Impact factor: 4.666

4.  Defective monocyte function in patients with systemic lupus erythematosus.

Authors:  R Phillips; R Lomnitzer; A A Wadee; A R Rabson
Journal:  Clin Immunol Immunopathol       Date:  1985-01

5.  Increased biosynthesis of complement components by cultured monocytes, synovial fluid macrophages and skynovial membrane cells from patients with rheumatoid arthritis.

Authors:  C de Ceulaer; S Papazoglou; K Whaley
Journal:  Immunology       Date:  1980-09       Impact factor: 7.397

6.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

7.  Decreased Fc receptor avidity and degradative function of monocytes from patients with systemic lupus erythematosus.

Authors:  S Katayama; D Chia; D W Knutson; E V Barnett
Journal:  J Immunol       Date:  1983-07       Impact factor: 5.422

8.  Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE).

Authors:  M Linker-Israeli; A C Bakke; R C Kitridou; S Gendler; S Gillis; D A Horwitz
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

9.  Membrane distribution and adsorptive endocytosis by C3b receptors on human polymorphonuclear leukocytes.

Authors:  D T Fearon; I Kaneko; G G Thomson
Journal:  J Exp Med       Date:  1981-06-01       Impact factor: 14.307

10.  Molecular mechanism for feedback regulation of C4 biosynthesis in guinea pig peritoneal macrophage.

Authors:  H S Auerbach; R D Baker; W J Matthews; H R Colten
Journal:  J Exp Med       Date:  1984-06-01       Impact factor: 14.307

View more
  7 in total

1.  Synthesis and regulation of the fourth component of complement (C4) in the human monocytic cell line U937: comparison with that of the third component of complement (C3).

Authors:  H Tsukamoto; K Nagasawa; S Yoshizawa; Y Tada; A Ueda; Y Ueda; Y Niho
Journal:  Immunology       Date:  1992-04       Impact factor: 7.397

2.  Presence of multiple abnormal immunologic markers is an independent prognostic factor of diffuse large B-cell lymphoma.

Authors:  Yiwen Cao; Zhenhua Liu; Wen Wu; Ying Qian; Qin Shi; Rong Shen; Binshen Ouyang; Pengpeng Xu; Shu Cheng; Jin Ye; Yiming Lu; Chaofu Wang; Chengde Yang; Li Wang; Weili Zhao
Journal:  Front Med       Date:  2019-01-31       Impact factor: 4.592

3.  Reduced expression of C1q-mRNA in monocytes from patients with systemic lupus erythematosus.

Authors:  F Moosig; F Damm; A Knorr-Spahr; M Ritgen; R A Zeuner; M Kneba; M Ernst; J O Schröder
Journal:  Clin Exp Immunol       Date:  2006-12       Impact factor: 4.330

4.  Production of the third and fourth component of complement (C3, C4) by smooth muscle cells.

Authors:  Y Ueda; K Nagasawa; H Tsukamoto; T Horiuchi; H Nishizaka; K Ikeda; Y Niho
Journal:  Immunology       Date:  1996-10       Impact factor: 7.397

5.  Effects of cell differentiation on the synthesis of the third and fourth component of complement (C3, C4) by the human monocytic cell line U937.

Authors:  H Tsukamoto; K Nagasawa; Y Ueda; T Mayumi; I Furugo; T Tsuru; Y Niho
Journal:  Immunology       Date:  1992-12       Impact factor: 7.397

6.  Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma.

Authors:  Cigall Kadoch; Jing Li; Valerie S Wong; Lingjing Chen; Soonmee Cha; Pamela Munster; Clifford A Lowell; Marc A Shuman; James L Rubenstein
Journal:  Clin Cancer Res       Date:  2013-11-04       Impact factor: 12.531

7.  Role of protein kinase C activation in synthesis of complement components C2 and factor B in interferon-gamma-stimulated human fibroblasts, glioblastoma cell line A172 and monocytes.

Authors:  I Watanabe; T Horiuchi; S Fujita
Journal:  Biochem J       Date:  1995-01-15       Impact factor: 3.857

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.